SOX9 Recombinant Monoclonal Antibody

說明書

中文名稱：

SOX9重組抗體
貨號：

CSB-RA202969A0HU
規格：

￥1320
圖片：
IHC image of CSB-RA202969A0HU diluted at 1:100 and staining in paraffin-embedded human colon cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

CSB-RA202969A0HU SOX9重組單克隆抗體是針對轉錄因子SOX9開發的高特異性科研用試劑。該抗體采用重組技術制備，具有嚴格的靶標識別能力，經實驗驗證可穩定應用于酶聯免疫吸附實驗（ELISA）和免疫組織化學（IHC）檢測，其中IHC推薦使用濃度為1:50至1:200。SOX9作為調控胚胎發育及組織分化的關鍵因子，在軟骨形成、干細胞維持和腫瘤發生等領域具有重要研究價值。本產品通過抗原親和純化工藝，確保抗體與SOX9蛋白表位的高效結合，實驗數據顯示其在多種組織樣本中能清晰呈現核定位信號，且與同類分子無交叉反應，適用于發育生物學、腫瘤機制研究及再生醫學相關實驗。建議使用者根據具體樣本類型優化孵育時間和二抗系統，以獲得最佳染色效果。
Uniprot No.：

P48436
基因名：

SOX9
別名：

Transcription factor SOX-9, SOX9
反應種屬：

Human
免疫原：

A synthesized peptide derived from human SOX9
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

5H12
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Transcription factor that plays a key role in chondrocytes differentiation and skeletal development. Specifically binds the 5'-ACAAAG-3' DNA motif present in enhancers and super-enhancers and promotes expression of genes important for chondrogenesis, including cartilage matrix protein-coding genes COL2A1, COL4A2, COL9A1, COL11A2 and ACAN, SOX5 and SOX6. Also binds to some promoter regions. Plays a central role in successive steps of chondrocyte differentiation. Absolutely required for precartilaginous condensation, the first step in chondrogenesis during which skeletal progenitors differentiate into prechondrocytes. Together with SOX5 and SOX6, required for overt chondrogenesis when condensed prechondrocytes differentiate into early stage chondrocytes, the second step in chondrogenesis. Later, required to direct hypertrophic maturation and block osteoblast differentiation of growth plate chondrocytes: maintains chondrocyte columnar proliferation, delays prehypertrophy and then prevents osteoblastic differentiation of chondrocytes by lowering beta-catenin (CTNNB1) signaling and RUNX2 expression. Also required for chondrocyte hypertrophy, both indirectly, by keeping the lineage fate of chondrocytes, and directly, by remaining present in upper hypertrophic cells and transactivating COL10A1 along with MEF2C. Low lipid levels are the main nutritional determinant for chondrogenic commitment of skeletal progenitor cells: when lipids levels are low, FOXO (FOXO1 and FOXO3) transcription factors promote expression of SOX9, which induces chondrogenic commitment and suppresses fatty acid oxidation. Mechanistically, helps, but is not required, to remove epigenetic signatures of transcriptional repression and deposit active promoter and enhancer marks at chondrocyte-specific genes. Acts in cooperation with the Hedgehog pathway-dependent GLI (GLI1 and GLI3) transcription factors. In addition to cartilage development, also acts as a regulator of proliferation and differentiation in epithelial stem/progenitor cells: involved in the lung epithelium during branching morphogenesis, by balancing proliferation and differentiation and regulating the extracellular matrix. Controls epithelial branching during kidney development.
基因功能參考文獻：
1. Results find SOX9 highly expressed in non-small cell lung cancer (NSCLC) tissues, and positively correlates with that of MALAT1. Moreover, SOX9 protein expression was higher in NSCLC tissues expressing highly especially MALAT1 mRNA. PMID: 29896925
2. results demonstrate that the inhibition of miR-30d attenuates the apoptosis and extracellular matrix degradation of degenerative human nucleus pulposus cells by up-regulating SOX9, suggesting a potential therapeutic target for intervertebral disc degeneration PMID: 30243741
3. Our study demonstrated that Reg IV positively regulates the expression of SOX9 and is involved in tumor cell invasion and migration in gastric cancer. PMID: 29587675
4. SOX9 may be involved in the tumorigenesis and progression of oral squamous cell carcinoma (OSCC). Furthermore, its cytoplasmic expression represents a potential predictive biomarker for tumor aggressiveness and OSCC prognosis. PMID: 30132562
5. This is supported by the fact that ECG correlates with the expression of SOX9 indicating that this biomarker probably plays an important role in the pathogenesis of gastric cancer and ECG formation. PMID: 29703178
6. role in regulation of extracellular matrix balance, the inflammatory process, and the immune response of inflamed dental pulp PMID: 29571909
7. Study found a positive relationship between LINC00052 and miR-101-3p, and a negative relationship between miR-101-3p and SOX9 in hepatocellular carcinoma (HCC) tissues. Besides, miR-101-3p was involved in LINC00052 inhibiting HCC cells proliferation and metastasis. At the molecular level, LINC00052 downgulated SOX9 to inhibit HCC cells proliferation and metastasis by interacting with miR-101-3p. PMID: 30098428
8. SOX9 expression is related to prognosis in patients with oesophageal squamous cell carcinoma, although it is not an independent prognostic factor. PMID: 29936467
9. the findings of this study establish the SOX9/CA9-mediated oncogenic pathway in glioma, the inhibition of which enhances the sensitivity of glioma cells to Temozolomide (TMZ) treatment, and thus highlights the value of developing small molecules or antibodies against the SOX9/CA9 pathway, for combination therapy with TMZ, in the more efficient management of glioma PMID: 29749469
10. Heterogeneous Expression of Embryonal Development Master Regulator SOX9 in Patients with Pancreatic Cancer PMID: 30168061
11. Melatonin inhibits cancer stem cell by down-regulation of SOX9-mediated signaling pathway in osteosarcoma PMID: 29689273
12. Our results demonstrate that the linc-ROR-miRNA-SOX9 regulatory network may represent a novel therapeutic target for esophageal squamous cell carcinoma PMID: 29237490
13. These results indicate that THRAP3 negatively regulates SOX9 transcriptional activity as a cofactor of a SOX9 transcriptional complex during chondrogenesis. PMID: 28770354
14. MiR-19a could promote cell viability and migration of chondrocyte via positively regulating SOX9 expression through NF-kappaB signaling pathway. PMID: 29306212
15. miR-185 inversely regulates SOX9 expression in non-small cell lung cancer. PMID: 29138830
16. Data suggest that the SOX9 transcription factor (SOX9)-fibroblast growth factor receptor 2 (FGFR2b) feed-forward loop has a lineage dependency role in pancreatic ductal adenocarcinoma (PDAC). PMID: 28796141
17. Depletion of KDM6A inhibits the expression of SOX9, Col2a1, ACAN and results in increased H3K27me3 and decreased H3K4me3 levels. PMID: 29171124
18. Our results demonstrate that SOX9 plays a crucial role in chordoma. Targeting SOX9 provides a new rationale for treatment of chordoma PMID: 28606919
19. Odd-skipped related 1 (OSR1) downregulated the activity of the Wnt signaling pathway by suppressing the expression of sex-determining region Y-box 9 (SOX9) and beta-catenin. PMID: 29660200
20. Sex determining region Y box 9 (Sox9) plays an important role in chemoresistance by the induction of stemness in pancreatic cancer cells. PMID: 28984791
21. Knockdown of SOX9 expression by RNA interference reduces cell proliferation and induces apoptosis of lung cancer cells, which was consistent with the results obtained from silencing the expression of LASP-1 in NCIH1650 cells. PMID: 29138807
22. This study provides evidence of a novel signaling pathway for TGF-beta in cartilage that involves post-translational stabilization of Sox9 protein through Smad2/3 and p38 signaling pathways. PMID: 27929080
23. In conclusion, these results highlight the potential therapeutic effects of Andro in treatment of chondrosarcoma via targeting the TCF-1/SOX9 axis. PMID: 28485543
24. These results identify a functional role for SOX9 in regulating colorectal cancer cell plasticity and metastasis, and provide a strong rationale for a rapamycin-based therapeutic strategy. PMID: 27571710
25. Sox9 is induced by TGF-beta in the kidney fibroblast and acted as an important downstream mediator of TGF-beta signaling in promoting renal fibrosis PMID: 29158184
26. Diagnostic tools such as whole-exome sequencing, targeted-gene sequencing and low-density CNV arrays, often miss CNVs within the SOX9 regulatory region. Yet, given the numerous reports, it is likely that CNVs in the SOX9 regulatory region may be a frequent genetic cause of 46,XX DSD. PMID: 28317102
27. Studied the role upregulation of RUNX2 in endocrine resistance in breast cancer. PMID: 28507152
28. OPN is a useful surrogate marker of SOX9 in hepatocellular carcinoma. PMID: 27457505
29. MicroRNA-494 promotes extracellular matrix degradation and apoptosis of degenerative human nucleus pulposus cells by directly targeting SOX9. PMID: 28427186
30. Klotho suppresses Sox9 upregulation and intranuclear translocation. Klotho inhibits high phosphate-induced osteogenic activity in human aortic valve interstitial cells. PMID: 28332126
31. Genetic variants of SOX9 are associated with susceptibility of gliomas. PMID: 27589569
32. we identified SOX9 as a functional target protein of miR-524-5p and found that SOX9 overexpression could counteracts the chemosensitizing effects of miR-524-5p. PMID: 27880941
33. Biomarker expression in pancreatic ductal adenocarcinoma (PDAC) of CXCR4, SMAD4, SOX9 and IFIT3 will be prospectively assessed by immunohistochemistry and verified by rt.-PCR from tumor and adjacent healthy pancreatic tissue of surgical specimen. PMID: 28356064
34. A critical level of endogenous active SOX9 needed to maintain colorectal tumor cell growth. PMID: 27429045
35. ERG and SOX9 are potential biomarkers for prediction of response to docetaxel treatment in metastatic castration-resistant prostate cancer patients. PMID: 27863438
36. We have provided evidence that truncating mutations in SOX9 (particularly exon 3 truncating mutations) are recurrent in colorectal carcinoma PMID: 27248473
37. This study suggested that G allele at rs12941170 was protective, which could decrease the risk for NSOCs from Western Han Chinese population. PMID: 28068523
38. HSP60 regulation of SOX9 ubiquitination mitigates the development of knee osteoarthritis. PMID: 27118120
39. Data show that SOX9 regulates CEACAM1 primarily via Sp1 and ETS1. PMID: 26885752
40. Sox9 confers stemness properties of hepatocellular carcinoma through Frizzled-7 mediated Wnt/beta-catenin pathway. PMID: 27105493
41. Data show that the gene encoding the transcription factor SOX9 was identified by a global transcriptomic approach as an HDAC9 target gene. PMID: 26930713
42. SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types PMID: 29121666
43. Sox9 and Ngn3, key transcription factors associated with pancreatic development. PMID: 27836003
44. Expression of bone morphogenetic protein (BMP) 4, an upstream stimulator of SOX9, was upregulated by CG. PMID: 27931264
45. Xenogeneic implantation of Sox9-overexpressing hUCMSCs embedded in the BMG/fibrin scaffolds promotes the formation of cartilage-like tissue without inducing evident host immune response. Therefore, Sox9-overexpressing hUCMSCs represent a promising cell candidate for cartilage tissue engineering. PMID: 28028895
46. KLF15 activates SOX9 expression directly. SOX9 is involved in KLF15 function during chondrogenic differentiation. PMID: 28923246
47. Tomo-Seq Identifies SOX9 as a Key Regulator of Cardiac Fibrosis During Ischemic Injury PMID: 28724751
48. High SOX9 expression is associated with glioblastoma. PMID: 27911279
49. These findings suggest that SOX9 may play an important role in tumor progression of Renal Cell Carcinoma and Bladder Cancer and it may be used as a biomarker of this malignancy. PMID: 28118628
50. Loss of DDRGK1 decreases SOX9 expression and causes a human skeletal dysplasia. PMID: 28263186
顯示更多

收起更多
相關疾病：

Campomelic dysplasia (CMD1); 46,XX sex reversal 2 (SRXX2); 46,XY sex reversal 10 (SRXY10)
亞細胞定位：

Nucleus.
數據庫鏈接：

HGNC: 11204

OMIM: 114290

KEGG: hsa:6662

STRING: 9606.ENSP00000245479

UniGene: Hs.647409

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human